A Qualitative Approach to a Better Understanding of the Problems Underlying Drug Shortages, as Viewed from Belgian, French and the European Union's Perspectives

被引:54
作者
Bogaert, Petronille [1 ]
Bochenek, Tomasz [1 ]
Prokop, Anna [2 ]
Pilc, Andrzej [3 ]
机构
[1] Jagiellonian Univ, Coll Med, Fac Hlth Sci, Dept Drug Management, Krakow, Poland
[2] Jagiellonian Univ, Coll Med, Fac Med, Chair Epidemiol & Prevent Med, Krakow, Poland
[3] Polish Acad Sci, Inst Pharmacol, Dept Neurobiol, Krakow, Poland
关键词
IMPACT;
D O I
10.1371/journal.pone.0125691
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The problem of drug shortages has been reported worldwide, gaining prominence in multiple domains and several countries in recent years. The aim of the study was to analyze, characterise and assess this problem in Belgium and France, while also adopting a wider perspective from the European Union. A qualitative methodological approach was employed, including semi-structured interviews with the representatives of respective national health authorities, pharmaceutical companies and wholesalers, as well as hospital and community pharmacists. The research was conducted in early 2014. Four themes, which were identified through the interviews, were addressed in the paper, i.e. a) defining drug shortages, b) their dynamics and perception, c) their determinants, d) the role of the European and national institutions in coping with the problem. Three groups of determinants of drug shortages were identified throughout this study: manufacturing problems, distribution and supply problems, and problems related to economic aspects. Currently, the Member States of the European Union are striving to resolve the problem very much on their own, although a far more focused and dedicated collaboration may well prove instrumental in coping with drug shortages throughout Europe more effectively. To the best of the authors' knowledge, this is the first qualitative study to investigate the characteristics, key determinants, and the problem drivers of drug shortages, focusing on this particular group of countries, while also adopting the European Union's perspective.
引用
收藏
页数:20
相关论文
共 55 条
[1]  
Agence nationale de securite du medicament et des produits de sante, 2014, INF SEC RUPT STOCK A
[2]  
All-Party Pharmacy Group, 2012, REP APPG INQ MED SHO, P30
[3]  
American Hospital Association, 2011, AHA SURV DRUG SHORT, P14
[4]  
[Anonymous], 2011, LANCET ONCOL, V12, P313, DOI 10.1016/S1470-2045(11)70087-0
[5]  
[Anonymous], 2010, LANCET, V376, P1712, DOI 10.1016/S0140-6736(10)62116-2
[6]  
[Anonymous], MED SHORT EUR HOSP
[7]  
[Anonymous], IMPACT DRUG SHORTAGE
[8]  
ASHP Drug Shortage Resource Center, 2014, DRUG SHORT CURR SHOR
[9]  
ASHP Expert Panel on Drug Product Shortages, 2009, Am J Health Syst Pharm, V66, P1399, DOI 10.2146/ajhp090026
[10]  
Autorite de la concurrence, 2012, AV 12 A 18 20 JUILL, P34